Look at the six major events in the biomedical technology industry in 2016
The development experience and lessons of the industry in 2016 can help biomedical technology investors to make investment decisions next year. This year biomedical sciences industry has experienced the same roller coaster development, starting from the middle of last year continued to decline this year, until after the Donald Trump rather than Hillary Clinton elected US president, we reduce the fear of price controls that makes The industry has recovered from a low point. Here is the performance of an index fund (iShares Nasdaq Biotechnology Index ETF):
01, IPO progress slows down
Last year, the US exchange-listed drug companies had 55 initial public offerings (IPOs), but this year the number was only 29. The slowdown in IPO rates is not unexpected. The main reason is that the rise in capital demand has led to a large number of companies preparing to request public funds, which have been resolved. The poor performance of the biomedical technology stock index certainly did not help these start-ups seek investors who are willing to buy their initial products.
Two biomedical technology companies of concern (but not necessarily current investments) are related to genetic editing: Editas Medicine and CRISPR Therapeutics. Both companies use a new technique called "aggregation rule interval short palindrome repetition" (CRISPR) to edit the patient's DNA. The use of new technologies will inevitably encounter related technical problems that need to be overcome, plus unresolved patent problems. This is what makes these two companies suitable for long-term investment opportunities, or is more suitable for inclusion in the watch list of most investors.
02, ongoing mergers and authorization transactions
As in previous years, there have been a large number of acquisitions and licensing transactions in the industry this year. The two most prominent ones are:
Pfizer acquired Medivation for $14 billion. Investors benefited from fierce bidding, and Sanofi initially realized a strong interest, but it was reported that other companies were actively involved.
Celgene invests $1 billion in JunoTherapeutics. This includes some equity investments, a 10-year agreement that Juno grants Celgene the right to treat immune cell therapy and autoimmune diseases outside the United States. This is a huge guarantee for the company's early research projects.
Body Lotion,Vaseline Lotion,Body Moisturizer,Body Cream
Guangzhou Lingxue Cosmetics Co., Ltd , https://www.gzlxgj188.com